The research would investigate the feasibility of a method for direct isolation and cloning of genes associated with states of disease, cell differentiation, or metabolic induction. Phase I studies will focus on steps in the process that currently limit the widespread use of subtractive nucleic acid hybridization as a means of isolating the target genes. In Phase II, this technology will be integrated and optimized to allow the cloning of any gene that is active in one cell type, but not another.Awardee's statement of the potential commercial applications of the research:The resulting technology will ultimately lead to Phase III development of a variety of commercial products for use in basic biological research and for possible clinical applications in the diagnosis and therapy of many diseases.National Institute of General Medical Sciences (NIGMS)
